The S&P/ASX 200 Index (ASX: XJO) is having a subdued start to the week. In afternoon trade, the benchmark index is down 0.3% to 8,844.3 points.
Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:
Image source: Getty Images
4DMedical Ltd (ASX: 4DX)
The 4D Medical share price is up a further 38% to $2.13. This respiratory imaging technology company's shares are rocketing again on Monday after it announced agreements with a leading global pharmaceutical company, Royal Melbourne Hospital, and Spectrum Medical Imaging to deploy its lung health analysis software. Management notes that the agreements, spanning to 2027, aim to support lung cancer screening, including the recently commenced National Lung Cancer Screening Program (NLCSP) in Australia, and improve lung health assessment. CEO and Founder, Andreas Fouras, said: "In parallel to our US efforts to bring CT:VQ to market, we are pleased to see progress on other products in the portfolio in countries where CT:VQ is yet to receive regulatory clearance."
DroneShield Ltd (ASX: DRO)
The DroneShield share price is up over 5% to $3.19. Investors have been buying this counter drone technology company's shares after they were added to the ASX 200 index at the September quarterly rebalance. DroneShield is one of nine ASX shares that will join the benchmark index when the market opens on 22 September. This news can boost volume on the buy side as it means index funds that track the ASX 200 will need to purchase shares. In addition, some fund managers have mandates that only allow them to buy shares from certain indices. This could open up DroneShield shares to them now.
Orthocell Ltd (ASX: OCC)
The Orthocell share price is up 5% to $1.19. This follows news that a new Remplir study demonstrated a compelling overall treatment success rate of 81.1% following nerve repair procedures. The regenerative medicine company's CEO, Paul Anderson, said: "We are delighted with the interim results from our Remplir RWE Study, validating the superior Remplir clinical outcomes, previously published in a highly regarded, peer reviewed journal. This performance is why more than 200 surgeons across more than 165 hospitals are now using Remplir and these numbers continue to grow." Remplir is a nerve repair product.
Resolute Mining Ltd (ASX: RSG)
The Resolute Mining share price is up 4.5% to 73.2 cents. Investors have been buying this gold miner's shares following the release of an updated mineral resources estimate from its Doropo Gold Project in Cote d'Ivoire. The project now has a total Measured, Indicated and Inferred MRE of 114 Mt grading 1.19 g/t Au for 4.4 Moz, which is a 28% increase from the previous MRE of 3.4 Moz.
